Trial · NCT03267940
Participant flow48
How many started, completed or left each group, period by period.
1 to 20 of 48
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Run-in Portion (Max. Exposure: 508 Days) | STARTED | Run-in Portion: PEGCISGEM | 9 | |
| Run-in Portion (Max. Exposure: 508 Days) | STARTED | Run-in Portion: PEGCISGEMATEZO | 9 | |
| Run-in Portion (Max. Exposure: 508 Days) | STARTED | Expansion Portion: PEGCISGEM | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | STARTED | Expansion Portion: PEGCISGEMATEZO Twice Weekly | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | STARTED | Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | STARTED | Expansion Portion: CISGEM | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | Received at Least 1 Dose of Study Drug | Run-in Portion: PEGCISGEM | 9 | |
| Run-in Portion (Max. Exposure: 508 Days) | Received at Least 1 Dose of Study Drug | Run-in Portion: PEGCISGEMATEZO | 9 | |
| Run-in Portion (Max. Exposure: 508 Days) | Received at Least 1 Dose of Study Drug | Expansion Portion: PEGCISGEM | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | Received at Least 1 Dose of Study Drug | Expansion Portion: PEGCISGEMATEZO Twice Weekly | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | Received at Least 1 Dose of Study Drug | Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | Received at Least 1 Dose of Study Drug | Expansion Portion: CISGEM | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | COMPLETED | Run-in Portion: PEGCISGEM | 1 | |
| Run-in Portion (Max. Exposure: 508 Days) | COMPLETED | Run-in Portion: PEGCISGEMATEZO | 2 | |
| Run-in Portion (Max. Exposure: 508 Days) | COMPLETED | Expansion Portion: PEGCISGEM | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | COMPLETED | Expansion Portion: PEGCISGEMATEZO Twice Weekly | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | COMPLETED | Expansion Portion: PEGCISGEMATEZO Once Weekly/Twice Weekly | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | COMPLETED | Expansion Portion: CISGEM | 0 | |
| Run-in Portion (Max. Exposure: 508 Days) | NOT COMPLETED | Run-in Portion: PEGCISGEM | 8 | |
| Run-in Portion (Max. Exposure: 508 Days) | NOT COMPLETED | Run-in Portion: PEGCISGEMATEZO | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03267940/flow